drugset / Trial / NCT06209606
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.
Timeline
- Start
- 2022-12-08
- Primary completion
- 2026-05
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Methylprednisolone | Other / unclassified | 40 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 5 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |